New analysis on Victoza reducing CV risk in type 2 diabetes

29 August 2017

An analysis presented at the European Society of Cardiology (ESC) Annual Congress has shown that Victoza (liraglutide) reduces the risk of major cardiovascular (CV) events in people with type 2 diabetes at high CV risk, irrespective of whether they have had a heart attack or stroke or not.

The new analysis of the LEADER trial showed this comparison between Victoza, an approved a human glucagon-like peptide-1 (GLP-1) analogue from Danish diabetes giant Novo Nordisk (NOV: N), and placebo.

It was presented at the Barcelona conference just three days after the announcement that the US Food and Drug Administration (FDA) had approved a new indication for Victoza to reduce the risk of major adverse CV events in adults with type 2 diabetes and established CV disease, strengthening the position as a leader in the GLP-1 class against the likes of Jardiance (empagliflozin), from Boehringer Ingelheim and Eli Lilly (NYSE: LLY).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK